<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a retrospective multicenter study of 12 children treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> on a compassionate basis (median age 5.5 y) </plain></SENT>
<SENT sid="2" pm="."><plain>Three patients (2 MDS/AML, 1 JMML) were refractory to first-line treatment, 8 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were in refractory first relapse, and one patient with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was in 2nd relapse after stem cell transplantation (SCT) </plain></SENT>
<SENT sid="3" pm="."><plain>CD33 expression exceeded 20% in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> was administered alone, at a unit dose of 3-9 mg/m2, once (3 patients), twice (3 patients), three (5 patients) or five times (1 patient) </plain></SENT>
<SENT sid="5" pm="."><plain>Mean follow-up was 128 days (8-585 d) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: There were three complete responses (25%) leading to further curative treatment (SCT) </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment failed in the other nine patients, and only one patient was alive at the end of follow-up </plain></SENT>
<SENT sid="8" pm="."><plain>NCI-CTC grade III/IV adverse events comprised hematological toxicity (n = 12), hypertransaminasemia (n = 2), <z:e sem="disease" ids="C0869403,C0700625,C0020517" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">allergy</z:e> and <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> (1 case each) </plain></SENT>
<SENT sid="9" pm="."><plain>There was only one major adverse event (grade IV <z:e sem="disease" ids="C0869403,C0700625,C0020517" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">allergy</z:e>) </plain></SENT>
<SENT sid="10" pm="."><plain>No case of <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> occurred </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: These results warrant a prospective trial of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> in a larger population of children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>